September 2022 Exploiting Dependence of Castration-Resistant Prostate Cancer on the Arginine Vasopressin Signaling Axis by Repurposing Vaptans "Men with advanced prostate cancer are treated by androgen deprivation therapy but the disease recurs as incurable castration-resistant prostate cancer (CRPC), requiring new Interrogation of prostate cancer patient sample data revealed that coexpression of AVPR1A and AVPR2 is

), the therapeutic benefits of the β-adrenergic receptor antagonist, propranolol, were described in benign

more Elucidation of active components and target mechanism in Jinqiancao granules for the treatment of prostatitis and benign prostatic hyperplasia GPCRs in Cardiology, Endocrinology, and Taste Blockade of endothelial

Neurocrine Biosciences Presents Data on Treatment of Adolescent Patients with Classic Congenital Adrenal Hyperplasia new Phase 2 data on the use of crinecerfont in adolescent patients with classic congenital adrenal hyperplasia

To chemically induce CCR9 degradation, we then developed the first PROTAC targeting the IABS of GPCRs In a proof-of-principle study, we succeeded in showing that our CCR9-PROTAC is able to reduce CCR9 levels

whereas OR51E1 and OR51E2 represent ubiquitously expressed ORs, although there are highly increased in prostate tissue, especially in prostate cancer (Maßberg D. and Hatt H. 2018). OR51E1 and OR51E2, initially assumed to be GPCRs only expressed in prostate tissue, play a role in prostate cancer epithelial cells proliferation via activation by β-ionone which initiates prostate cancer cell

the company’s investigational candidate for the treatment of Cushing’s disease, congenital adrenal hyperplasia

The intertwining roles of caveolin, oxytocin receptor, and the associated signalling pathways in prostate

Autocrine Proteinase-Activated Receptor (PAR) signaling in PC3 prostate cancer cells.

Autocrine proteinase-activated receptor signaling in PC3 prostate cancer cells.

Clinical, Pathophysiologic, Genetic, and Therapeutic Progress in Primary Bilateral Macronodular Adrenal Hyperplasia

ENDO 2024 for Atumelnant in Two Ongoing, Open-Label Studies for the Treatment of Congenital Adrenal Hyperplasia

Endo 2024 For Atumelnant In Two Ongoing, Open-Label Studies For The Treatment Of Congenital Adrenal Hyperplasia

Clinical, pathophysiologic, genetic and therapeutic progress in Primary Bilateral Macronodular Adrenal Hyperplasia